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The prevalence of prehypertension and Stage 1 hypertension continues to increase despite being amenable to non-pharmacologic
interventions. Iyengar yoga (IY) has been purported to reduce blood pressure (BP) though evidence from randomized trials is
lacking. We conducted a randomized controlled trial to assess the eﬀects of 12 weeks of IY versus enhanced usual care (EUC)
(based on individual dietary adjustment) on 24-h ambulatory BP in yoga-na¨ ıve adults with untreated prehypertension or Stage 1
hypertension. In total, 26 and 31 subjects in the IY and EUC arms, respectively, completed the study. There were no diﬀerences in
BPbetween thegroups at 6 and12 weeks. In theEUC group,24-hsystolic BP(SBP),diastolicBP (DBP)and mean arterialpressure
(MAP) signiﬁcantly decreased by 5, 3 and 3mmHg, respectively, from baseline at 6 weeks (P < .05), but were no longer signiﬁcant
at 12 weeks. In the IY group, 24h SBP was reduced by 6mmHg at 12 weeks compared to baseline (P = .05). 24h DBP (P < .01) and
MAP (P < .05) decreased signiﬁcantly each by 5mmHg. No diﬀerences were observed in catecholamine or cortisol metabolism to
explain the decrease in BP in the IY group at 12 weeks. Twelve weeks of IY produces clinically meaningful improvements in 24h
SBP and DBP. Larger studies are needed to establish the long term eﬃcacy, acceptability, utility and potential mechanisms of IY to
control BP.
1.Introduction
Hypertension remains a major public health issue with
the latest data from the National Health and Nutrition
Examination Survey (NHANES) revealing that 65 million
adults in USA have hypertension [1]. Hypertension is asso-
ciated with increased risks of stroke, cardiovascular disease
and chronic kidney disease [2]. Patients with high normal
blood pressure (BP) [systolic BP (SBP) 130–139mmHg or
diastolic BP (DBP) 80–89mmHg] fall into the category of
prehypertensive [3] and are at an increased risk for adverse
cardiovascular events compared with normotensive controls
[4]. Lifestyle modiﬁcations (LSM) are recommended as ﬁrst
lineapproachforbothprehypertensiveandStage1hyperten-
sion patients (SBP 140–159mmHg or DBP 90–99mmHg)
[5]. LSM include weight loss, dietary recommendations and
increased physical activity which can reduce SBP by 2–
20mmHg [3], but are often diﬃcult to sustain [6].
Thereisemergingdatathatmind-bodytherapies(MBTs)
may be useful in managing modest elevations in BP [7].
Yoga, a movement-based MBT, is especially attractive as a
candidate therapy in the management of elevated BP because
ofitswideappealtoWesternersanditscombinationofgentle
physical activity, slowed regulated breathing and meditation.
If yoga practice were to be eﬀective in preventing, delaying or
treatingmildhypertension,thiscouldtranslateintoaclinical2 Evidence-Based Complementary and Alternative Medicine
and health economic beneﬁt in people motivated enough to
pursue this kind of treatment. There are several reports in
the literature on the eﬀects of various yoga programs on BP
[8–16]; however, most of these are case series or studies with
methodological limitations.
The objective of this randomized controlled trial was
to rigorously evaluate the cardiovascular and physiologic
eﬀects of a 12-week structured Iyengar yoga (IY) program
compared with an enhanced usual care (EUC) intervention
emphasizing dietary approaches on reducing average SBP as
measured by 24-h ambulatory BP monitoring (ABPM) in
adults with untreated prehypertension to Stage I hyperten-
sion.
2. Methods
2.1. Participants. Participants included 78 yoga-na¨ ıve adults
between the ages of 22 and 69 years with untreated
SBP ≥130mmHg but <160mmHg, and DBP <100mmHg.
Major exclusion criteria included: pregnancy or postpartum
<3 months; current use of any medications or dietary
supplements known to aﬀect BP; body mass index (BMI)
>40kg/m2; practice of IY in previous 12 months, or active
practice of any other MBT more than two times per
month; diabetes mellitus; cardiovascular disease; autonomic
neuropathy; current tobacco use; renal insuﬃciency; and
>10 alcoholic drinks per week in women and >15 drinks in
men. Subjects were recruited by ﬂyers placed in the hospital
and university campus and by advertisements placed in local
papers and online advertising using craigslist. The University
of Pennsylvania Institutional Review Board approved the
trial, and all subjects provided written, informed consent.
The trial was registered at the Clinical Trials website:
NCT00328666.
2.2. Study Protocol. Screening BP and heart rate (HR) were
measured in the morning after a 12-h fast using a Datascope
Accutorr Plus machine with an appropriate sized cuﬀ after
individuals were seated for 5min. Three readings were
obtained, separated by 1-min intervals and the average
of these readings determined eligibility. Eligible subjects
returned to the General Clinical Research Center (GCRC)
for an inpatient stay at Weeks 0, 6 and 12 for ABPM
which was recorded over 24h using Spacelabs model 90207
monitors [17]. Subjects remained in the GCRC during the
inpatient stay and were sedentary. Data was determined to
be satisfactory if there were at least 48 (80%) acceptable
readings (SBP between 70 and 280mmHg and DBP between
40and150mmHg)between6a.m.and12:00midnight,and
six acceptable readings between midnight and 6 a.m. If any
three consecutive readings averaged >180mmHg for SBP, or
>110mmHg for DBP, the participant was discontinued.
2.3. Intervention. Over 23 months, seven cohorts containing
8–12 participants per cohort were recruited sequentially and
randomized to either EUC or IY after completing the week 0
visit and prior to discharge from their ﬁrst GCRC overnight
stay. Participants randomized to IY attended twice weekly
Table 1: IY class structure and components.
Component (a) Time
Instructor introduction and
organizational issues 5min
Set up and take attendance 5min
Asanas (a)
Savasana (corpse pose) 5min
Cross bolsters 5min
Supta baddha konasana (supine bound
angle pose) (a) 5min
Supta swastikasana (supine fortunate
pose) (a) 5min/side
Bharadvajasana (a twisting pose) 3 × 30 s/side
Pavannamuktasana (release of wind pose) 5min
Adho mukha virasana (downward facing
hero pose) 5min
Adho mukha swastikasana (downward
facing fortunate pose) (a) 1min/side
Adho mukha svanasana (downward
facing dog) 1min
Uttanasana (standing forward bend) 1min
Janu sirsasana (seated forward bent with
bent leg) 1min/side
Upavisthakonasana (seated forward bend
with wide legs) 3min
Paschimottanasana (full forward bend) (a) 1min
Savasana (corpse pose) (a) 5min
Ujjayi (the conqueror) pranayama (a) 5min
End of class attendance (a)
Total class time (including 1min
transitions) (a) ∼71min
(a)Included in the home program.
70min IY classes for the ﬁrst 6 weeks (ﬁrst class was within
7 days after week 0 visit) and then once a week for the
following 6 weeks. Classes were not open to the public and
were taught by two IY-certiﬁed instructors. In each class,
2–10 participants were led through a sequence of adjusting
the body into timed postures (asanas) and breathing tech-
niques (pranayama) using props. The IY program (Table 1)
was developed by IY-certiﬁed instructor, Joan White, with
input from IY founder B.K.S. Iyengar and included speciﬁc
postures that were easy to adapt for older, obese populations.
During the second-half of the program (Weeks 6–12), IY
participants also participated in home practice using a 25-
min DVD. Each participant kept a home diary to document
frequency and duration of the home practice. Participants
who missed three consecutive or four total IY studio classes
were discontinued. Participants randomized to IY did not
receive any instructions or guidance regarding LSM.
Participants randomized to EUC classes attended four
1-h group classes that met during Weeks 1, 2, 3 and 8
with 30-min individual phone contact at Weeks 5 and
10. Classes were taught by the same registered dietitian
(S.V.). The classes were designed to include motivational andEvidence-Based Complementary and Alternative Medicine 3
behavioral components educating participants about LSM to
reduceelevatedBPincludingweightreduction/maintenance,
sodium reduction, alcohol restriction and increasing intake
of fruits, vegetables and low-fat, calcium-rich foods. EUC
participants who missed more than one of the ﬁrst three
classes were discontinued.
At each visit, body weight was measured on a calibrated
scale. Subjects were instructed to record all food and
beverages consumed for three assigned days prior to Weeks
0, 6 and 12. Data was analyzed using Nutrition Data Systems
for Research software, version 4.05, University of Minnesota.
In order to assess the eﬀect of IY on the hypothalamic-
adrenal axis, we measured salivary cortisol and several
urinary and blood biomarkers. Caﬀeine, alcohol and exercise
were discouraged 8h prior to collection. Salivary cortisol
samples were collected between 7 a.m. and 8 a.m. and
sealed into a container until analyzed by an ELISA assay
(Salimetrics). Urine was collected over 24h at each visit and
stored at 4◦C during collection and transferred to a −70◦C
freezer until analyzed. Blood was obtained after a 12-h fast
at Weeks 0, 6 and 12. Urine cortisol was measured after
extracting with dichloromethane using a radioimmunoassay
kit (Siemen Medical Solutions Diagnostic, Los Angeles, CA,
USA) Urine sodium and potassium were measured using
a Laboratory Instrument 943 ﬂame photometer. Plasma
Aldosterone was also measured using the radioimmunoassay
kit (Siemen Medical Solutions Diagnostic). Plasma Renin
was measured by IRMA using a kit by Diagnostic Systems
Laboratories, Webster, TX, USA. Plasma Metanephrines
were measured by ELISA using a kit by ImmunoBiological
Laboratories, MN55432.
The following psychometric evaluations were performed
at Weeks 0, 6 and 12 to determine the eﬀect of IY on
mood, anxiety, stress and health-related quality of life as
compared with EUC. The speciﬁc tests performed included
the Proﬁle of Mood States (POMS), the Perceived Stress
Survey (PSS) and the Short-form Health Survey (SF-36).
Research staﬀ manually scored the completed questionnaires
and the results were entered into the database.
2.4. Statistics
2.4.1. Sample Size. All sample size calculations were done
and veriﬁed using Power and Precision version 2.04 (Datax-
iomSoftwareInc.),whichestimatedthatwitha15%dropout
rate, we would need to randomize 30 subjects per group. The
sample size was based on an 80% power calculation to detect
a 4mmHg SBP diﬀerence between groups.
2.4.2. Statistical Analysis. Diﬀerences in baseline characteris-
ticsbetweensubjectswhocompletedandthosewhodropped
out were tested using t-tests for continuous variables and
chi-squared tests for categorical variables. Outcomes within
the IY group and within the EUC group were tested by
comparing means at baseline to means at Week 6 and means
at Week 12 using t-tests on the equality of means. Outcomes
for the IY group relative to the EUC group were tested by
comparing the diﬀerence in means between baseline and
Assessed for eligibility (n = 130)
Excluded (n = 52)
N o tm e e t i n ge n t r yc r i t e r i a( n = 45)
Decided not to participate (n = 7)
Randomized (n = 78)
Allocated to IY (n = 46)
Received IY (n = 43)
Allocated to EUC (n = 32)
Received EUC (n = 32)
Week 6
Withdrawn (n = 0)
Week 6
Withdrawn (n = 11)
Reason withdrew:
Protocol criteria (n=4)
Personal decision (n = 7)
Week 12
Withdrawn (n = 9)
Reason withdrew:
Protocol criteria (n = 5)
Adverse event (n = 3)
Personal decision (n = 1)
Week 12
withdrawn (n = 1)
Reason withdrew:
Protocol criteria (n = 1)
Figure 1: Study ﬂow diagram.
Week 6 and between baseline and Week 12 for the IY arm
and the EUC group. The standard t-test of diﬀerences in
means assumes that the variances are equal. This assumption
may be too strong. If violated, it may underestimate the true
standard error and lead to P-values that are too small. We
used Satterthwaite’s formula to correct the standard error
and P-values when needed.
3. Results
3.1. Study Participation and Retention. Figure 1 shows par-
ticipant retention. Dropout rate exceeded the estimated 15%
intheIYarm.Becausethedropoutratewasimbalanced(zero
in the EUC arm at this time), randomization was changed
from 1 : 1 to 4 : 1 (IY to EUC) for the last cohort to try and
balance group numbers.
3.2. Demographics. Baseline demographics of enrolled sub-
jects are shown in Table 2. There were no signiﬁcant baseline
diﬀerences between those who dropped out or completed or
between completers when comparing treatment groups.4 Evidence-Based Complementary and Alternative Medicine
Table 2: Baseline demographics by treatment (a).
Characteristics IY EUC
(n = 46) (n = 32)
Male, n 23 16
Female, n 23 16
Race, n
African American 18 14
Asian/native Hawaiian/Paciﬁc Islander 3 1
Caucasian 21 16
Hispanic 3 0
Other 1 1
Age (years) 48.2 ± 1.6 48.3 ± 2.4
Weight (kg) 86.4 ± 3.1 87.7 ± 3.4
BMI (kg/m2) 29.6 ± 0.9 30.5 ± 1.0
SBP (mmHg) 140 ± 1 140 ± 1
DBP (mmHg) 87 ± 18 6 ± 1
(a)R e s u l t sr e p o r t e da sm e a n( s t a n d a r de r r o r ) .
3.3. Twenty-Four Hour AMBP. SBP and DBP of 24h at
W e e k s0 ,6a n d1 2a r ea v a i l a b l ef r o m2 6p e o p l ei nt h eI Y
group and 31 people in the EUC group, which is shown
in Table 3. At 6 weeks, 24h SBP signiﬁcantly improved in
the EUC group when compared with the IY group (P value
between groups = .04). There was no signiﬁcant diﬀerence
in 24h DBP at 6 weeks between groups and no diﬀerence
i ne i t h e r2 4 hS B Po rD B Pa t1 2w e e k sb e t w e e ng r o u p s .
Among IY participants, there was no signiﬁcant change in
24h SBP or DBP at 6 weeks compared to baseline, but both
measures improved at 12 weeks (P = .05 for SBP and P <
.01 for DBP). Within the EUC group, 24h SBP and DBP
signiﬁcantlydecreasedfrombaselineat6weeks(P =.02,SBP;
P < .05, DBP), but changes in these measures at 12 weeks
were no longer signiﬁcant. This data is shown graphically in
Figure 2.
3.4. Weight and BMI. There was no signiﬁcant change in
weight or BMI over time between groups. However, weight
and BMI decreased signiﬁcantly in the EUC group at 12
weeks compared to baseline. Weight decreased from 88.8 ±
3kg at Week 0 to 87.2 ± 0.7kg at Week 12 (with a change of
−1.6kg, P = .02) in the EUC group. There was no change
in weight in the IY group (85.5 ± 3.9kg at Week 0 and
87.0 ± 1.8kg at Week 12; change of 1.5kg, P = 0.4). BMI
also decreased signiﬁcantly in the EUC group at 12 weeks (P
< .05) but remained unchanged in the IY group at 12 weeks.
3.5. Diet Composition. The IY group did not receive any
individualized dietary instructions or guidelines. There was
a signiﬁcant decrease in energy intake at 6 weeks in the
EUC group compared to the IY group that was due to a
decrease in total fat and carbohydrates. EUC participants
also had a signiﬁcant decrease in dietary sodium intake at
6 weeks compared to the IY group, yet sodium levels had
started to revert towards baseline at 12 weeks. Urine sodium
levels also showed a signiﬁcant decrease at 6 weeks implying
dietary compliance with a sodium restricted diet; however,
at 12 weeks, urine sodium levels had increased and were
no longer signiﬁcant. At 12 weeks, the change in potassium
intake was signiﬁcantly greater in the EUC group when
compared with the IY group.
3.6. Biochemical Measures. There were no diﬀerences over
time between treatments in plasma levels of aldosterone,
renin or metanephrines or in urinary or salivary cortisol
concentrations. There were no signiﬁcant changes in routine
chemistry measures between groups at 12 weeks.
3.7. Psychometric Evaluations. There were no signiﬁcant
inter- or intra-group diﬀerences in psychometric data at 6
or 12 weeks for the POMS and PSS. However, the SF-36
health transition subscale was statistically signiﬁcant for the
EUC group at 6 weeks (P = .02) but was not sustained at
12 weeks. Correlations between psychometric data and the
change in 24h SBP were found in PSS (P = .03), POMS
(P = 0.4) and Global scores (P = .001) in both groups. There
was a correlation between the change in the total SF-36 and
changeinsalivarycortisol(P =.02)forbothgroups(datanot
shown).
4. Discussion
This is the ﬁrst randomized controlled clinical trial in USA
assessing the eﬀects of IY compared with dietary measures
on 24h ABPM in patients with prehypertension or Stage I
hypertension. Although we did not ﬁnd that IY signiﬁcantly
improved any measured endpoint over the EUC group, our
data demonstrated that IY produced clinically meaningful
reductions in SBP and DBP at 12 weeks compared to
baseline within the IY group. The mean 24h SBP decreased
by 6mmHg at 12 weeks compared to baseline. This is
comparable to estimated reductions in SBP when following
individual established LSM including weight loss, DASH
diet, sodium reduction or physical activity [3]a n dw a s
numerically greater than the change in mean 24h SBP in
the EUC group at 12 weeks. Data from a meta-analysis of
individual data for 1 million adults from 61 prospective
observational studies of BP and mortality demonstrated that
even a small 2-mmHg fall in mean SBP was associated with
a 7% lower risk of ischemic heart disease (IHD) death and
a 10% lower risk of stroke death [18] emphasizing that
even small reductions in SBP in large populations can have
important cardiovascular morbidity and mortality beneﬁts.
Psychological stress is a risk factor for hypertension [19–
21] and the Canadian Hypertension Society recognizes the
role of stress management techniques in managing hyper-
tension [22, 23]. Reduction of stress using transcendental
meditation has been shown to decrease BP in African
American hypertensives [24, 25]. Various forms of yoga also
claim to reduce stress by integrating the body and mind.
Although there are several published studies investigating
the eﬀects of various forms of yoga on hypertension [8, 9,
12, 13, 26], most of these were uncontrolled case reportsEvidence-Based Complementary and Alternative Medicine 5
Table 3: Changes in 24h BP parameters (a).
IY EUC
Week 0 Week 6 Week 12 Week 0 Week 6 Week 12
SBP (mmHg) 132 (3) 133 (2) 126 (3)∗ 135 (3) 130 (2)∗∗ 131 (2)
DBP (mmHg) 83 (2) 83 (1) 78 (2)∗∗∗ 82 (2) 79 (1)∗∗ 80 (1)
MAP (mmHg) 99 (2) 99 (1) 94 (2)∗∗ 99 (2) 96 (1)∗∗ 97 (2)
Heart rate (mmHg) 70 (2) 70 (1) 68 (2) 69 (2) 67 (1) 67 (1)
(a)R e s u l t sr e p o r t e da sm e a n( s t a n d a r de r r o r ) .
∗P = .05, ∗∗P < .05, ∗∗∗P < .01.
110
115
120
125
130
135
140
145
150
8am 8pm 8am
24HR SBP change in EUC group
SBP WK0
SBP WK6
SBP WK12
(a)
65
70
75
80
85
90
8am 8pm 8am
DBP WK0
DBP WK6
DBP WK12
24HR DBP change in EUC group
(b)
105
110
115
120
125
130
135
140
145
24HR SBP change in yoga group
8am 8pm 8am
SBP WK0
SBP WK6
SBP WK12
(c)
65
70
75
80
85
90
95
DBP WK0
DBP WK6
DBP WK12
8am 8pm 8am
24HR DBP change in yoga group
(d)
Figure 2: Changes in mean 24h SBP and DBP in the IY and EUC groups at randomization, 6 and 12 weeks.
or small cohort studies conducted in India with signiﬁcant
methodological limitations [8, 11, 12]. There are only
three randomized controlled trials of any form of yoga for
hypertension [9, 10, 26] .T h em o s tr e c e n ts t u d yw a sa n8 -
week pranayama and asana yoga program conducted in 27
untreated hypertensive patients and 27 controls in Thailand
[26]. The experimental group signiﬁcantly reduced SBP by
24mmHg at 8 weeks compared to 2mmHg increase in the
control group. DBP signiﬁcantly improved by 18mmHg
in the experimental group compared to an increase of
2mmHg in the control group. Details regarding methods
and accuracy of BP measurement were not included. In
India, 33 hypertensive adults were randomly assigned to
three groups (yoga, medications only, or no therapy) and
were followed for 11 weeks [9]. Yoga was performed at
home for 6h per week; at the end of the study, SBP reduced
by an impressive 33mmHg compared with 4mmHg in the
control group and 24mmHg in the poorly described drug
therapy group. The diﬀerences were signiﬁcant compared
with both control and drug treatment. In an older RCT6 Evidence-Based Complementary and Alternative Medicine
from England, 43 patients with known hypertension, most
of whom were already medically treated, were randomized
to yoga plus biofeedback or usual care [10]. Treatment
reducedSBPby26mmHgversus9mmHginthecontrol(P <
.005). However, this study used a mixed intervention which
included biofeedback in addition to yoga, which was more
like TM and did not include any movement.
Thereareseverallimitationsthatcanaﬀectinterpretation
of the data. Subjects enrolled in the trial were possibly
more likely than the general population to be motivated to
pursue a lifestyle modiﬁcation such as yoga as a therapy
for hypertension and this can lead to a self-selected study
populationbeingenrolledinthetrial.Althoughrandomized,
the trial was unblinded and though we included the EUC
control group, it was an active control. While blinding is
ideal to eliminate measurement bias, it is not feasible with
behavioral interventions. The EUC intervention produced
signiﬁcant changes in some BP parameters and although
numerically smaller than the IY group, at 12 weeks we were
underpowered to detect a statistically signiﬁcant diﬀerence
between groups. The lack of diﬀerences between groups may
be attributed to both the unanticipated high dropout rate in
theIYgroupandthedurationofthetrialwhichwasprobably
too short to detect greater changes in the IY group as it is
apparent that changes in BP in the IY group took longer to
occur.
The EUC group produced a signiﬁcant reduction in 24h
SBP at 6 weeks compared to the IY group as well as a
signiﬁcant within group improvement in DBP. While these
variables were not statistically signiﬁcant at 12 weeks either
between groups or within the EUC group, they were still
clinically meaningful and met the primary aim of decreasing
SBP by 6mmHg from baseline. Changes in 24h SBP and
DBP were comparable to changes seen in previous clinical
trials assessing the eﬀects of dietary modiﬁcations alone [27,
28] and in combination with other lifestyle modiﬁcations on
BP[29].BodyweightinEUC-randomizedsubjectsdecreased
signiﬁcantly within this group at 12 weeks compared to
baseline. EUC participants made signiﬁcant improvements
in energy, fat, carbohydrates and sodium intake at 6 weeks,
yet all variables started to revert towards baseline at 12
weeks. This was seen particularly with urine sodium which
showed a signiﬁcant decrease at 6 weeks implying dietary
compliance with a sodium-restricted diet; however, at 12
weeks, urine sodium levels had increased and were no
longer signiﬁcant indicating diﬃculty in maintaining dietary
sodium restriction. These ﬁndings are supported by others
revealing that dietary recommendations are hard to follow
over time [6].
Another limitation is that the two intervention groups
met with unequal frequency and this can introduce con-
founding. Due to the high attrition rate in the IY group
which exceeded expectations, a change was necessitated in
the randomization scheme for the last cohort from 1 : 1 to 4
: 1 (IY: EUC). Although we acknowledge this as a limitation,
there were no diﬀerences in the baseline demographics in
the IY group in the subjects who dropped out compared
to the subjects who completed. Twenty participants (43%)
randomized to IY did not complete, thereby reducing
the numbers of completers and thus the power of the trial.
Of the IY non completers, 60% were due to not being able
to adhere to the class schedule. This may be due to several
reasons. IY is not an aerobic form of exercise like other
more Westernized forms of yoga, and subjects recruited into
the study were “yoga-na¨ ıve” and may have expected a more
traditional type of yoga and may have been discouraged by
the rigid style of our IY program. The yoga program was
also designed as “top heavy” program which decreased in
intensity over the trial. Yoga practice for na¨ ıve yoga subjects
requires slow transition with increase in intensity of the yoga
program over a few months.
We sought to determine the role of reductions in stress
as a mechanism for the BP pressure changes in our subjects
using questionnaires and salivary cortisol. Our failure to
ﬁnd such association in the IY group was disappointing.
Other studies evaluating yoga practice suggests that yoga
may reduce oxidative stress [30] and endothelial-dependent
vasodilatation in patients with established coronary artery
disease [16]. Additional studies are needed incorporating
measures of oxidative stress and endothelial function.
Our data demonstrates that the eﬀects of IY on BP at
12 weeks as assessed by 24h ABPM were comparable or
greater than that produced by an EUC intervention in adults
with prehypertension and stage 1 hypertension. This pilot
has provided useful data and experience that we can use for
future studies. Speciﬁcally, when designing a future trial, we
would include three groups and assess the combination of
EUC and yoga versus intervention alone, we would enroll
subjects for a longer duration (24 weeks) to detect greater,
more sustained reductions in BP in the yoga groups. We
would redesign the yoga program with speciﬁc attention to
improving adherence and gradually increasing yoga practice
over the course of the trial. We would also consider using a
less rigid, more aerobic type of yoga that is more available
and accessible to the public and therefore more likely to be
incorporated into patients’ lifestyles as a long-term lifestyle
adjustment. However, given the general safety proﬁle of yoga
and general public appeal, we feel it is important to fund
additional studies in order to establish the long-term eﬃcacy
and the potential mechanisms in BP reductions associated
withyogatherapyinpatientswithprehypertensionandStage
1 hypertension.
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